Literature DB >> 6608821

Myristylation of gag-onc fusion proteins in mammalian transforming retroviruses.

A Schultz, S Oroszlan.   

Abstract

Four cell lines producing transforming proteins encoded by three mammalian oncogenes (fes, abl, and ras) were investigated for incorporation of [3H]myristate into gag-onc fusion proteins. Using 5-min pulse-labelings, fusion proteins of Abelson murine leukemia virus, Gardner-Arnstein strain of feline sarcoma virus (FeSV), and Snyder-Theilen strain of FeSV were shown to be myristylated. In a 4-hr pulse, p29gag-ras of rat sarcoma virus (RaSV) was also shown to incorporate radiolabel. The fatty acid was recovered from this labeled protein by acid hydrolysis, and identified by reverse-phase thin-layer chromatography to be [3H]myristic acid. The results indicate that substitution of viral gag sequences by cellular oncogene sequences does not abolish their ability to become post-translationally modified by this long chain fatty acid (A. Schultz and S. Oroszlan, J. Virol. 46, 355-361). It is assumed that in the fusion proteins the myristyl moiety is linked through an amide linkage to the amino-terminal glycine as previously found for several retroviral gag precursor polyproteins (L. E. Henderson, H. C. Krutzsch, and S. Oroszlan, Proc. Natl. Acad. Sci. USA 80, 339-343). The possible role of myristylation of transforming proteins is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608821     DOI: 10.1016/0042-6822(84)90409-4

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Development and characterization of a panel of monoclonal antibodies against the catalytic domain of the human fes proto-oncogene product.

Authors:  A van Bokhoven; H L van Duijnhoven; M Jücker; A J Roebroek; W J van de Ven
Journal:  Mol Biol Rep       Date:  1992-02       Impact factor: 2.316

Review 2.  Acylation of viral and eukaryotic proteins.

Authors:  R J Grand
Journal:  Biochem J       Date:  1989-03-15       Impact factor: 3.857

3.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Poorly expressed endogenous ecotropic provirus of DBA/2 mice encodes a mutant Pr65gag protein that is not myristylated.

Authors:  N G Copeland; N A Jenkins; B Nexø; A M Schultz; A Rein; T Mikkelsen; P Jørgensen
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

5.  Capsid protein VP4 of poliovirus is N-myristoylated.

Authors:  A V Paul; A Schultz; S E Pincus; S Oroszlan; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

6.  Association of a major transcriptional regulatory protein, ICP4, of herpes simplex virus type 1 with the plasma membrane of virus-infected cells.

Authors:  F Yao; R J Courtney
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

7.  Development and analysis of a transformation-defective mutant of Harvey murine sarcoma tk virus and its gene product.

Authors:  M O Weeks; G L Hager; R Lowe; E M Scolnick
Journal:  J Virol       Date:  1985-05       Impact factor: 5.103

8.  Identification and some biochemical properties of the major XBL gene product of bovine leukemia virus.

Authors:  N Sagata; J Tsuzuku-Kawamura; M Nagayoshi-Aida; F Shimizu; K Imagawa; Y Ikawa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

9.  Acylation of monocyte and glomerular mesangial cell proteins. Myristyl acylation of the interleukin 1 precursors.

Authors:  S L Bursten; R M Locksley; J L Ryan; D H Lovett
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

10.  Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line.

Authors:  G Q Daley; R A Van Etten; P K Jackson; A Bernards; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.